ZP5-9676 dose

Phase 3Small molecule

ZZero Point Five Therapeutics

ZP5-9676 dose is one of 6 small molecule programs targeting Helminthiasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HelminthiasisActive, not recruiting

HelminthiasisPhase 3

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Helminthiasis

#DrugCompanyPhaseTrials

Niclocide

Biltricide

Vermox

1 4

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—5

Cydectin

MMedicines Development for Global Health

Approved

—6

ZP5-9676 dose

ZZero Point Five Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Helminthiasis

NCT06128447

Clinical

Trials by Indication[1]

Helminthiasis1 trial

Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)

Recruiting·ZZero Point Five Therapeutics·Phase 3·NCT06128447·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ZP5-9676 dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZP5-9676 dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZP5-9676 dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zero Point Five Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZero Point Five Therapeutics

ZP5-9676 dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Helminthiasis1 trial

References

Drug Info

Quick Facts

Related News